A Rebound with Staying Power May Be in the Cards for This Beat-Up Medical Devices ETF

Why It Matters

A technical rebound in IHI could channel fresh capital into the medical‑device segment, while its lag behind XLV highlights a valuation gap that risk‑aware investors may exploit.

Key Takeaways

• IHI downtrend since start 2026, but MACD buy signals reappeared
• Recent bounce forms potential double‑bottom near 50‑day moving average
• ETF retests historic support zone in mid‑40s, previously sparked multi‑year rally
• Relative weakness versus XLV deepens, 14‑month RSI hits record oversold

Pulse Analysis

The medical‑device industry has long been a bellwether for innovation‑driven growth, and the iShares U.S. Medical Devices ETF (IHI) serves as a convenient proxy for investors seeking exposure. After a steep decline that began in January 2026, IHI has underperformed both the S&P 500 and the broader health‑care sector, prompting concerns about sector momentum. Yet the ETF’s recent technical developments—most notably a fresh MACD bullish crossover and a 14‑day RSI nudging above the neutral 50 mark—signal that the market may be re‑evaluating its risk profile, especially as investors hunt for undervalued niches amid a generally volatile equity environment.

Chart analysts point to a classic double‑bottom formation emerging around the 50‑day moving average, a pattern that historically precedes sustained recoveries. The ETF’s price is also testing a well‑established support band in the mid‑40s, a level that previously acted as a springboard for multi‑year rallies in 2022, 2023, and the early 2020s. These technical cues are reinforced by a marginally higher low recorded in early June, suggesting that buying pressure may be gaining traction. When viewed on a monthly log scale, the support zone aligns with prior bounce points, adding weight to the hypothesis that IHI is nearing a structural bottom rather than merely experiencing a short‑term correction.

From an investment standpoint, the convergence of short‑term bullish signals and long‑term support strengthens the risk‑reward profile of IHI. However, the ETF’s relative weakness versus the State Street Health Care Select Sector SPDR (XLV) remains stark; the IHI/XLV ratio has slumped to its deepest historical trough, and the 14‑month RSI on that spread is at an all‑time oversold reading. For disciplined investors, this divergence could represent a contrarian entry point, especially if the broader health‑care sector continues its upward trajectory. Nonetheless, the technical setup does not guarantee an immediate reversal, and prudent portfolio construction should balance exposure with the sector’s inherent regulatory and reimbursement risks.